Academic Journal
Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells
| العنوان: | Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells |
|---|---|
| المؤلفون: | Eun-Ju Ko KMD, PhD, Eun-Bin Kwag PhD, Ji-Hye Park KMD, PhD, Sung-Hyuk Cho MS, So-Jung Park KMD, PhD, Mi-Kyung Jung KMD, PhD, In-Cheol Kang PhD, Hwa-Seung Yoo KMD, PhD |
| المصدر: | Integrative Cancer Therapies, Vol 24 (2025) |
| بيانات النشر: | SAGE Publishing, 2025. |
| سنة النشر: | 2025 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | In this study, we investigated the synergistic effect of co-administration of osimertinib and HAD-B1 using gefitinib-resistant non-small cell lung cancer cells, HCC827-GR. HAD-B1 is composed of 4 natural drugs, Panax Notoginseng Radix, Panax ginseng C. A. Meyer, Cordyceps militaris, and Boswellia carterii Birdwood, and has been reported to have therapeutic effects on patients with advanced non-small cell lung cancer in several studies. Resistance to gefitinib in HCC827 cells was acquired through MET activity. Co-treatment with osimertinib and HAD-B1 reduced the cell viability of HCC827-GR cells. In addition, phosphorylation of MET and ERK were effectively suppressed for HCC827-GR cells. And, compared to when osimertinib and HAD-B1 were administered alone, cell proliferation was significantly inhibited and apoptosis was effectively induced when osimertinib and HAD-B1 were co-administered to HCC827-GR cells. We found that the synergistic effect of osimertinib and HAD-B1 combination therapy resulted in cancer cell death and cell cycle arrest by targeting the ERK and mTOR signaling pathways. In conclusion, this study confirmed that the combination of osimertinib, a third-generation anticancer drug, and HAD-B1, a natural anticancer drug, had a potentially synergistic effect on non-small cell lung cancer resistant to EGFR-targeted anticancer drugs. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1552-695X 15347354 |
| Relation: | https://doaj.org/toc/1552-695X |
| DOI: | 10.1177/15347354241307006 |
| URL الوصول: | https://doaj.org/article/44cc8d37190145ecaeea61988076d257 |
| رقم الانضمام: | edsdoj.44cc8d37190145ecaeea61988076d257 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 1552695X 15347354 |
|---|---|
| DOI: | 10.1177/15347354241307006 |